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Abstract
Purpose—Genome-scale clinical sequencing is being adopted more broadly in medical practice.
The National Institutes of Health developed the Clinical Sequencing Exploratory Research
(CSER) program to guide implementation and dissemination of best practices for the integration
of sequencing into clinical care. This study describes and compares the state of the art of
incorporating whole-exome and whole-genome sequencing results into the electronic health
record, including approaches to decision support across the six current CSER sites.
Methods—The CSER Medical Record Working Group collaboratively developed and completed
an in-depth survey to assess the communication of genome-scale data into the electronic health
record. We summarized commonalities and divergent approaches.
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Results—Despite common sequencing platform (Illumina) adoptions, there is a great diversity of
approaches to annotation tools and workflow, as well as to report generation. At all sites, reports
are human-readable structured documents available as passive decision support in the electronic
health record. Active decision support is in early implementation at two sites.
Conclusion—The parallel efforts across CSER sites in the creation of systems for report
generation and integration of reports into the electronic health record, as well as the lack of
standardized approaches to interfacing with variant databases to create active clinical decision
support, create opportunities for cross-site and vendor collaborations.
Keywords
clinical decision support; clinical sequencing; decision support rules; electronic health record;
electronic medical record; next-generation sequencing
INTRODUCTION
Background to the study
Clinical sequencing is an area of rapid growth, as laboratories, medical centers, and
hospitals adopt this method of comprehensively scanning the human genome for genomic
variants associated with clinical disease or pharmacogenomic effects.1 Clinical sequencing
impacts multiple facets of clinical care, such as processing of large-scale genomic data;
reporting of results, including results to diagnose the presenting condition; integration of
results into the medical record; and support of genome-enabled clinical decision making. To
guide the development of best practices for the integration of clinical sequencing into
clinical care, as well as to research the ethical, legal, and psychosocial implications of
delivering broad genomic data into the clinic, the National Human Genome Research
Institute, in collaboration with the National Cancer Institute, funded the Clinical Sequencing
Exploratory Research (CSER) Program.2 Currently composed of six leading academic
medical centers, CSER is working collaboratively to incorporate sequence data into the
clinical care of patients and to examine the relevant ethical, legal, and psychosocial issues.
Each site is completing a clinical genomic trial (whole-exome sequencing (WES) or whole-
genome sequencing) with a unique patient population. The acceleration in uptake of WES
outside the research setting is illustrated by the Baylor experience, in which clinical WES
for direct patient care was offered beginning in November 2011. In the first 18 months, the
laboratory has reported more than 1,000 WES results and currently receives ~200 clinical
test requests monthly. The CSER consortium members awarded funding by the National
Institutes of Health in 2011 are Baylor College of Medicine (BCM), Brigham and Women's
Hospital–Harvard Medical School (BWH), The Children's Hospital of Philadelphia (CHOP),
the Dana-Farber Cancer Institute (DFCI), the University of North Carolina (UNC), and the
University of Washington (UW).
The CSER Electronic Medical Record Working Group (CSER EMR WG) was created to
explore informatics issues related to annotation and prioritization of genomic variants, as
well as to the integration of genomic results into the EMR/electronic health record (EHR)
and EHR-enabled clinical decision support (CDS). The CSER EMR WG (chaired by P.T.-
H.) includes representation from each CSER site and the National Institutes of Health. The
initial goal was to systematically describe and compare the current state across the CSER
sites regarding how WES and whole-genome sequencing results are incorporated into the
EHR, including approaches to decision support. This work is complementary to the special
issue article on “Opportunities for Genomic Clinical Decision Support Interventions”3 by
the Electronic Medical Records and Genomics Network,4 which describes opportunities for
genomic CDS informed by the literature on traditional computerized CDS. Our work takes a
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bottom-up approach (examining current practices at the CSER sites), whereas the Electronic
Medical Records and Genomics article takes top-down approach (describing an ideal state
and requirements to achieve this state) to elucidating the future directions for genomic CDS.
Background on the six current CSER sites
The six initial CSER sites5 represent projects looking at the issue of generating and
incorporating next-generation sequencing (NGS) data (WES and whole-genome sequencing)
across a broad range of clinical settings to study the implementation and impact of genomic
medicine. The sites are exploring outcomes including (i) the communication of results to
their target populations, (ii) the preferences of their participants with respect to return of
incidental findings, (iii) the impact of reporting NGS to participants, (iv) how best to report
and store NGS data, (v) the incorporation of novel decision support technologies and
solutions, and (vi) the use of NGS as a diagnostic modality. Table 1 describes the patient
populations and unique features at each site.
MATERIALS AND METHODS
The CSER EMR WG developed a survey to describe and compare across the CSER sites
how NGS results are being incorporated into the EHR, including approaches to decision
support. Table 2 provides an overview of the survey, and Figure 1 illustrates graphically in
shaded form the scope of the survey.
Over a 3-month period, the CSER EMR WG members drafted and refined the survey, which
was then completed by each of the six sites in early 2013. Each site analyzed and
summarized the results for one of the six main sections of the survey, using a qualitative
approach. For certain questions, additional clarifying information was sought during the
analysis and summarization, which was reviewed by all the sites. The discussion section
includes material from CSER EMR WG teleconferences and in-person meetings in which




All six CSER network sites are performing massively parallel sequencing using the Illumina
HiSeq platform (San Diego, CA) and analyzing sequence data for germline mutations
associated with inherited disease and/or risk of disease. BCM and DFCI are focused on
cancer (Table 1) and thus they are also analyzing tumor samples for the presence of somatic
alterations.
Five CSER sites are performing NGS locally, and one site is outsourcing NGS followed by
on-site variant confirmation by Sanger sequencing. BCM and BWH are performing NGS in
a Clinical Laboratory Improvement Amendments (CLIA)–certified laboratory setting. The
other sites are performing NGS in a research setting followed by Sanger confirmation of
variants in a CLIA–certified laboratory (Table 3). Most sites are planning for a transition of
NGS to a CLIA–certified laboratory in the near future.
Each site has built a local bioinformatics workflow for variant annotation and interpretation
(Table 3). All sites have incorporated multiple public data sources for variant annotation as
part of their bioinformatics workflow. In addition, each site has built tools to incorporate
locally derived NGS data for variant annotation, such as local allele frequencies or tracking
of previously ascertained sequence variants. All sites incorporate manual or semi-automated
curation of sequence variants by searching the medical literature and/or relevant locus-
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specific databases to determine the clinical significance of sequence variants before
reporting.
All sites report different categories of information (Table 3) based on whether a variant is
related to the disease phenotype, a medically actionable incidental finding, or other
incidental but otherwise deemed reportable finding (e.g., carrier status, pharmacogenetic
information). Each site has developed its own strategy, described in detail elsewhere,6 for
how to classify and report incidental information. Several sites incorporate patient choice to
receive certain types of incidental genomic information with opt-in or opt-out categories. All
sites provide an indication-specific, focused report for potentially diagnostic information and
also report incidental findings not related to the disease phenotype as additional information
or in a separate report. In addition to relevant literature references, most of the CSER sites
provide links in their reports to websites that provide additional information regarding
variant classification and interpretation, such as OMIM,7 PubMed,8 RefSeq,9 dbSNP,10
GeneTests,11,12 GeneReviews,13–15 Clinicaltrials.gov,16 and PharmGKB,17 as relevant. As a
result of the heterogeneity apparent in Tables 1 and 3, each site has developed its own
custom annotation workflow. Currently, these bioinformatics tools are not being shared, and
commercial tools are not being used.
Variant databases/knowledge bases
The capabilities and characteristics of site-specific, accumulated variant databases/
knowledge bases (VDBKBs) have implications for what structured and computable data can
be sent to the EHR. External and internal VDBKBs are a critical component of NGS
diagnostic processes. The goal of these processes is to determine whether any of the tens of
thousands to millions of variants identified by NGS are clinically important (e.g., associated
with the indication for testing, a medically actionable incidental finding, or having a
significant pharmacogenomic association). The need for these assessments and the creation
of local VDBKBs stems from the fact that the NGS platforms currently available do not
include tools for annotation of the variants they report nor are they integrated with
VDBKBs.
The sites reported the use of different external variant and gene databases (Table 3).
External variant databases that catalog reported associations between specific variants and
known clinical phenotypes serve as a first-pass filter for annotation. However, thoroughly
evaluating NGS data often requires verifying reported associations and searching for other
potentially important variants that have not yet been associated with clinical phenotypes.
This task is particularly challenging because most annotation features available for filtering
provide suboptimal sensitivity and/or specificity. External databases with information on
variant frequencies or gene-level annotations are particularly useful in this context.
In addition to utilizing these external databases, each CSER site has developed a custom
local VDBKB to manage its internal variant information and support its reporting process
(Table 4). These systems record the variants identified in each patient and most CSER sites
are also recording their internal variant assessments. Investigating the clinical implications
of variants can be a time-consuming process; therefore, it is useful to store variant
classifications so that they can be leveraged if a variant is identified again in another patient.
BWH uses VDBKB annotation software (GeneInsight, Boston, MA)6 that is commercially
available. The other sites have developed their own systems.
Reporting of results into the EHR
The systems used for report generation (before integration of the report into the EHR) are
unique to each site (Table 4). Reporting is semi-automated (manual at CHOP), involving a
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combination of expertise in genetics, genomics, bioinformatics, and laboratory medicine/
pathology using custom systems for report generation, including the site's local VDBKB.
Four sites send the same report(s) to all providers/patients. CHOP has separate reports for
each group. DFCI and BCM have a tumor board–specific report. BCM has a more in-depth
clinical report for external providers. The UW report has the first section designed for
nongeneticists and later sections aimed at experts in molecular variants. Each of the sites
uses a different laboratory information management system (LIMS) (Table 4) that is either
locally developed or involves custom adaptations to a commercial platform.
The destination systems for reports are both commercial and custom-developed EHRs
(Table 4). Four sites use a single EHR and do not have partner sites, whereas UNC and UW
have partner sites with separate EHRs. UW has a heterogeneous EHR environment (Table
4), using Cerner,18 Sorian,19 and Epic20 EHRs. BWH, DFCI, and UNC are using custom-
developed EHRs to report NGS results while making plans to report into the commercial
EHRs in the future.
Despite the heterogeneity in workflows, VDBKBs, bioinformatics tools, LIMS, and EHRs
(Tables 3 and 4), the common end result at all sites is a PDF human-readable structured
document designed to be sent to the EHR (analogous to a pathology or other text report).
Several CSER sites also report to outside labs that are not part of the CSER project, using
their normal reporting process. Some sites also provide structured reporting in machine-
readable format. Due to a lack of standards in report content, structure, coding, generation,
and LIMS (Table 4), current EHRs are not able to process these structured reports because
their format is unique to each site. For a subset of actionable indication and incidental
findings, UW uses structured laboratory data (molecular testing results pathway) in the
SunQuest clinical laboratory system for active decision support.
Communication of results to providers
All sites feel that it is important to have highly trained personnel in medical/molecular
genetics available to the ordering physician. Each laboratory has identified genetic
counselors, molecular geneticists, or medical geneticists to communicate with the ordering
physician. In addition, the majority of sites make the medical director of the lab available to
ordering physicians as needed to explain more complex results.
Sites estimated that conversations to explain the implications of results, discuss
interpretation of uncertain variants, and answer questions typically take 15–30 min. The
ability to effectively explain the results to ordering physicians was felt to be an important
challenge in scaling up the process. The BCM laboratory, currently the largest clinical WES
CSER testing site, has already had to increase the number of staff who perform this specific
function.
Handling of changing variant/annotation information
As new genomic discoveries are made, genomic findings may be reclassified over time, and
other medical knowledge relevant to an NGS analysis or test interpretation may be gained.
Therefore, each CSER site has considered the challenge of reinterpreting genomic events
and what, if any, actions are required when new information is available for a patient's
genome report. The results of this survey demonstrate the wide spectrum of study policies
across the sites for the reanalysis of genomic data and the disclosure and reporting
mechanisms for new information. The diversity of approaches across the CSER sites
highlights the challenges of integrating new genomic information into clinical care given the
rapid pace of scientific discovery.
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CSER sites have segregated into one of two overarching options when it comes to disclosure
of new genomic information that may impact a patient's clinical management: (i) strict
nondisclosure of new information (DFCI, UW) or (ii) disclosure of new information if
logistically feasible (Table 4). The BWH site has an automated method for disclosure using
GeneInsight. Automated e-mail alerts are sent to clinicians when a variant is reclassified in a
manner that generates a “high” alert, and clinicians receive “medium-” and “low- priority”
alerts in batch form or on a weekly basis.21 A “high” or “medium” alert reflects a possible
change in treatment (e.g., uncertain significance to pathogenic or pathogenic to
nonpathogenic category), whereas a low-level alert specifies less substantial reclassifications
(e.g., benign to likely benign). Other sites have opted for semi-annual reviews (UNC) or
periodically as determined by the diagnostic lab (BCM, CHOP).
Regarding incidental findings that do not directly relate to the diagnostic question under
evaluation but that could impact decision making in a broader clinical context, one site
(UNC) has opted to issue amended reports that include new data. However, all other sites
that would issue new information plan to do so only for variants that fall within the original
indication for testing where this original assessment may include a “general genome report”
that assesses highly penetrant conditions independent of a prior probability of disease.
CDS
Given the growing number of reportable and actionable genes, the ideal approach to NGS
CDS in the EHR would include a combination of active (e.g., alerts inside the EHR
triggered by context) and passive CDS (e.g., reports requiring providers to seek out and
review reports).22
Because all sites use PDF documents for passive CDS (Table 4), we explored how the sites
ensure clinicians are made aware of the reports. Two organizations (DFCI and UW) used
features built in to the EHR to deliver sequence results (with notification) to a wide range of
clinical stake-holders, whereas two locations (BWH and BCM) sent e-mails (no protected
health information) outside the EHR to staff at the clinic where the order was placed and
provided verbal notification for more complex cases. At BWH, the e-mails provide deep
links that enable clinicians to authenticate and access relevant information or navigate to the
information through a system integrated with the EHR under a patient genetic summary
table. A medical geneticist at a fourth location (UNC) provided results verbally to study
subjects and solicited informed consent for results to be entered into the EHR. In addition to
the built-in notification features of the EHR, UW also directly contacted the primary
provider for a subset of the participants.
Active decision support rules were functional at two organizations, BWH and UW (Table
4). BWH developed custom decision support external to, but integrated with, its custom
(locally built) EHR. This system, along with medication data from the EHR, provides
pharmacogenomics decision support and sends notifications when variants are reclassified.
UW is using native features in its commercial EHR (Cerner) to implement alerts as part of
pilot efforts for selected variants for patients enrolled in the CSER study by building on
prior UW pilot work.23
Other CDS approaches are also used. Two organizations (UNC, UW) enhance their reports
with clickable links to supporting materials as a variant of passive decision support. BCM
has put significant effort into developing an iPad application providing the test report in a
more dynamic platform. The tablet application allows control of the content and direct
educational links (glossary, OMIM, PubMed) independent of the current limitations of the
EHR at the study site as well as the variety of EHRs used by hospitals outside the study
receiving test results as a simple PDF.
Tarczy-Hornoch et al. Page 6














Across the sites there is a common sequencing approach (Illumina HiSeq) and a common
end point (PDF text providing passive CDS). Despite this commonality, there is great
diversity of workflow, bioinformatics tools, and approaches starting from sequence data and
ending with report generation, which presents both opportunities and challenges for the
community.
A key reason for this diversity is that each site has its own approach to annotating variants
(Table 3), with its own informatics tools and overall workflow. This heterogeneity is
independent of NGS platform and results from the manual annotation currently required of
NGS data (Figure 1) and different decisions around this annotation process at each site
(Table 3). Another cause of diversity in workflow and tools is that each site has its own
internal VDBKB to capture site-specific assessments of variants (Table 4). Unfortunately,
VDBKB content cannot yet be shared across sites due to lack of standardization. A
consequence of this heterogeneity is that the same variant in a sequence may not be
annotated or reported on in the same way across the sites. There are a number of National
Institutes of Health–supported initiatives, including ClinVar24 and a proposed resource for
the identification and dissemination of consensus information on genetic variants relevant
for clinical care (described in RFA-HG-12-016, ref. 25) to address the current duplication
and heterogeneity of internal VDBKBs.
Passive CDS in the EHR is implemented at all sites as human-readable structured
documents. The ability to easily generate a PDF report independent of the workflow leading
to the report, and the ability of virtually any commercial or custom EHR system to accept a
PDF report, suggests this is likely to be a common first step to genomic decision support.
However, this approach has the known risks of passive decision support,22 which are
substantially exacerbated by the complexity of NGS.
Active CDS thus will be necessary as NGS-based testing is increasingly adopted, and as the
number of genes and variants deemed actionable/reportable for a given patient rises.26
Providers cannot be expected to read and remember all variants for a given patient via a
passive CDS. Active CDS triggered by context (e.g., drug–gene interactions at the time of
electronic order entry) will be critical to effectively scaling up EHR-based CDS of NGS
results. EHRs, particularly those of commercial systems, include decision support engines
that can be adapted for active genomic CDS subject to the availability of trigger
conditions.27 Institutions have published literature about using CDS engines for
pharmacogenomics decision support using different types of genomic data. For example, the
University of Utah used limited single-nucleotide polymorphism and allele data to pilot
pharmacogenomic decision support for CYP2C9.28 St Jude Hospital (Memphis, TN) used
data from the DMET Plus array (Affymetrix, Santa Clara, CA 1,936 genomic variants in 225
genes) and the Cerner EHR to implement a set of pharmacogenomics decision support rules
for 29 CYP2D6 alleles and 9 TMPT alleles.29 Two CSER sites are extending this work to
NGS (Table 4). UW is building on its proof-of-concept work23 and extending the standard
single-gene molecular testing result mechanism to put multiple actionable
pharmacogenomics variants into the EHR in a computable representation. These data can
then be used by the UW commercial EHR for active CDS. This approach is consistent with
the recommendation made by Masys et al.,30 which involves putting only the actionable
variants into the EHR as discrete data rather than all the NGS data. This approach is also
consistent with the model presented by the Electronic Medical Records and Genomics
consortium.31 Representing actionable variants via a clinical LIMS single-gene molecular
testing result reporting data structure could generalize to any LIMS and any EMR; however,
it is difficult to scale up because a new “test” would need to be created for each gene. BWH
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is using an external tool (GeneInsight) integrated into the EHR through a single sign-on
mechanism that passes patient context. GeneInsight sends structured data into EHRs to
support CDS rules that rely on these data (e.g., supplying data to the EHR needed to provide
a pharmacogenomic alert that appears at the time of electronic order entry). Both CSER
active CDS approaches have the potential to be implemented at other sites.
A challenge to scaling up active CDS is that currently computable rules cannot be
automatically derived or created from the VDBKB. Although not explicitly asked in the
survey, four of the six sites stated that they felt more sophisticated (and standardized)
biomedical informatics tools for interpretation of sequence variants are needed in order to
effectively scale up NGS diagnostics. The emerging discipline of translational
bioinformatics32 includes as its focus these types of translational tools. The change of
variant/annotation information over time magnifies the challenge of maintaining these rules.
These challenges are independent of the NGS method and the approach to delivering the
results into the EHR and are inherent to the nature of NGS. The need to re-annotate is
especially an issue for the sites disclosing new genomic information (Table 4).
A final barrier to putting actionable variant NGS data into the EHR is poor adherence to
existing standards to represent genomic variants, such as the guideline proposed by the
Human Genome Variation Society33 (in contrast to adopted standardized coding systems
such as the International Classification of Diseases, 10th revision).37 This challenge is
magnified by the lack of any VDBKB collective that would feed actionable variant results
into the EHR. Mark Hoffman (of the Cerner EHR company) has over the past 8 years begun
to put into the Cerner system an open source ontology along these lines,34 working toward a
vision of a genome-enabled EHR35 to enable a more generalizable and scalable approach to
personalized medicine.36 Ultimately, adoption of such standardized ontologic approaches
will be key to enabling sharing of active genomic decision support rules across organizations
and EHR vendors.
CDS alone is not sufficient and needs to be augmented by a mechanism to provide human-
to-human communication. All sites feel it is important to provide the ordering physician
access to highly trained personnel in medical/molecular genetics. This need is independent
of the EHR environment and reflects broader perspectives in the genetics community. Given
the complexity and nuances of interpreting genomic test results, as well as the possible
involvement of different medical stakeholders with widely varied perspectives and genomic
knowledge, there is a need for better leveraging of standard EHR mechanisms for person-to-
person consultation (e.g., provider-to-provider messaging embedded in commercial EHRs
such as inboxes and electronic consult workflows).
The issues above and the heterogeneity in approaches to variant identification, annotation,
prioritization, VDBKBs, and reporting tools (Tables 3 and 4) has led each CSER site to
build bioinformatics tools and workflows for the four intermediate steps between sequence
data and decision support outlined here (Figure 1). This represents significant past and
ongoing investment in bioinformatics infrastructure within and across the sites. Based on the
current study and the work of the CSER EMR WG, it appears that these tools are too closely
linked to local variations in approaches (Tables 3 and 4 ) to be generalizable across the sites,
even if they are open source. A number of early-phase companies are attempting to fill this
gap between the sequence data and the EHR. BWH uses the GeneInsight and Alamut
applications in their workflow. CHOP uses Cartagenia and Alamut. The CSER EMR WG is
thus exploring opportunities for cross-site collaboration across the steps in Figure 1 as part
of the recently formed CSER Coordinating Center.
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We conclude that future directions to maximize the ability to scale up NGS for clinical use
include (i) more cross-site collaboration in creation, curation, and integration of VDBKBs;
(ii) ensuring these knowledge bases are able to generate both human-readable and
computable reports (and standardizing the vocabulary or ontology used to code the
computable reports); (iii) development of standards for automating the translation of
information in VDBKBs into active decision support rules; (iv) development of best
practices for integrating biomedical informatics into clinical and communication workflows;
and (v) collaboration with vendors on adapting their active CDS (both EHR and related
genetic system vendors as well as the emerging third-party NGS decision support vendors).
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Figure 1. This figure created by the National Institutes of Health Clinical sequencing exploratory
Research (CSER) electronic Medical Records Working Group (EMR WG) shows the typical
CSER site workflow from specimen acquisition through the reporting of whole-exome or whole-
genome results into the EMR
As described in the text, each of the six CSER sites has its own site-specific workflow and
its own variant database/knowledge base. The focus of the CSER EMR WG (and the survey
presented in this article) is indicated by the shaded areas of the figure.
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Table 1
Populations and features of the six current Clinical Sequencing Exploratory Research sites
Site–Project name Population Unique site features
BCM – BASIC3 Pediatric patients with newly diagnosed high-
risk solid tumors including brain tumors
• Tablet-based platform and graphical display
• Return of results to pediatric oncologists and parents
• Both germline and tumor sequencing reported for each patient
BWH/HMS – MedSeq Patients with cardiomyopathy and a healthy
population
• Whole-genome sequencing rather than whole-exome
sequencing
• Creating and testing novel ways of integrating next-generation
sequencing data into the care of patients
• Randomized controlled trial
CHOP – PediSeq Pediatric patients with hearing impairments,
mitochondrial disorders, sudden cardiac
arrest, and intellectual disability
• Enabling substantial phenotype capture at the point of care to
assist with variant decision processes
DFCI/Broad – CanSeq Patients with metastatic lung or colon
adenocarcinoma
• Utilizing data to inform treatment decisions
• Tumor sequencing
UNC – NCGENES Patients with selected clinical conditions with
a likely genetic etiology: familial cancer,
neuromuscular disorders, microcephaly,
cardiomyopathy, retinitis
• Implementing whole-exome sequencing in traditionally
underserved populations throughout North Carolina
• Randomized controlled trial
UW – NEXT MEDICINE Patients in whom a hereditary predisposition
toward colon cancer and/or polyps is
suspected
• Identification of novel CRCP-related genes
• Randomized controlled trial
BCM, Baylor College of Medicine; BWH, Brigham and Women's Hospital–Harvard Medical School; CHOP, The Children's Hospital of
Philadelphia; CRCP, colo-rectal cancer polyposis; DFCI, Dana-Farber Cancer Institute; UNC, University of North Carolina; UW, University of
Washington.
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Table 2
Overview of survey
Area of survey Characteristics
Context Germline vs. somatic sequencing of tumors, sequencing platform, sequencing laboratory, approach to
CLIA certification, data sources used for annotation and referenced in reports, approach to “binning” of
results, and nature of the study population
Variant databases – knowledge
bases
Which databases are used to curate variants and annotations, how these databases are integrated with
clinical workflow, how variants are presented to molecular diagnostic staff for interpretation and sign-out,
how databases assist with report writing and/or rule generation, and linkages between variant databases
and EHR decision support tools
Reporting of results into the EHR Which EHR(s) are used, if the NGS/EHR process is generalized or specific to the site's CSER, systems
currently used for EHR report generation, NGS laboratory information management systems used,
interfaces to the EHR for reporting, structure of reports, report generation processes, customization of
reports by the audience, routing of results, and reporting tools external to the EHR being utilized
Communication of results to
providers
Whether consultation regarding NGS results is provided and if so, by whom; length of consultation; and
current capacity to scale up
Handling of changing variant/
annotation information
Content included in the consent process, whether reports are updated subsequent to receiving new
information, and if so, how this is achieved
Clinical decision support Type of decision support (passive vs. active), mechanisms to ensure that all providers can view key
content, which subset of results are used for decision support, and further characterization of active
decision support systems and of how these systems operate
CLIA, Clinical Laboratory Improvement Amendments; CSER, Clinical Sequencing Exploratory Research; EHR, electronic health record; NGS,
next-generation sequencing.
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Table 3
Overview of Clinical Laboratory Improvement Amendments (CLIA) model, variant annotation, and report
generation by CSER site
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ESP, National Heart, Lung, and Blood Institute GO Exome Sequencing Project exome variant server (evs.gs.washington.edu/EVS); HGMD,
Human Gene Mutation Database (http://www.hgmd.cf.ac.uk); HGNC, HUGO Gene Nomenclature Committee (http://www.genenames.org);
OMIM, Online Mendelian Inheritance in Man (http://www.omim.org).
BCM, Baylor College of Medicine; BWH, Brigham and Women's Hospital–Harvard Medical School; CHOP, The Children's Hospital of
Philadelphia; CLIA, Clinical Laboratory mprovement Amendments; CSER, Clinical Sequencing Exploratory Research; DFCI, Dana-Farber Cancer
Institute; UNC, University of North Carolina; UW, University of Washington; VUS, variant of uncertain significance.
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Table 4
Overview of variant database, report generation, EHR, reporting, and decision support by CSER site
BCM BWH CHOP DFCI UNC UW
VDBKB Custom local Custom local (available
commercially
GeneInsight)
Custom local Custom local Custom local Custom local
Report generation Custom semi-automated Custom semi-automated Manual Custom semi-automated Custom semi-automated Custom semi-automated



















LIMS Custom local GeneInsight Lab plus
custom local linked to
PowerPath
ThermoFisher Nautilus CoPath Geneus
Currently operational EHR Epic Custom EHR Epic Custom EHR WebCis custom EHR Epic – outpatient,
Sorian – one inpatient
site, Cerner – two
inpatient sites and
oncology






Passive decision support PDF PDF PDF PDF PDF PDF
Machine-readable structured reporting No Yes, machine readable
(XML, coded variants)
No Yes, machine readable
(coded variants – hg19
and HCNG)
No Yes, machine readable
(coded gene-linked
results)
Active decision support No Yes (custom) No No No Yes (leveraging Cerner)
Other decision support iPad application with
clickable links
No No No Clickable links Clickable links
Disclosure of new genomic
information
b
Yes Yes Yes No Yes No
BCM, Baylor College of Medicine; BWH, Brigham and Women's Hospital–Harvard Medical School; CHOP, The Children's Hospital of
Philadelphia; CSER, Clinical Sequencing Exploratory Research; DFCI, Dana-Farber Cancer Institute; EHR, electronic health record; HCNG,
HUGO Gene Nomenclature Committee; LIMS, laboratory information management system; N/A, not applicable; UNC, University of North
Carolina; UW, University of Washington; VDBKB, variant database/knowledge base; WES, whole-exome sequencing.
a
For the Baylor CSER project only the focused exome report is provided. Outside physicians can request the expanded report after receiving the
focused report.
b
“Disclosure of New Genomic Information”: Each CSER site has thus considered the challenge of reinterpreting genomic events and what, if any,
actions are required when new information is available for a patient's data.
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